NYSE : EBS
Emergent BioSolutions Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 6.81 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 349.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 349.17M |
| Enterprise Value | 797.67M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 51.27M |
| Shares Outstanding | 51.27M |
| Shares Change (YoY) | -5.35% |
| Shares Change (QoQ) | -8.67% |
| Owned by Insiders (%) | 4.33% |
| Owned by Institutions (%) | 88.83% |
| Float | 49.05M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 9.63 |
| PS Ratio | 0.45 |
| Forward PS | 0.54 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 4.39 |
| P/FCF Ratio | 4.06 |
| P/OCF Ratio | 3.57 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.04 |
| EV / EBITDA | 3.40 |
| EV / EBIT | 5.68 |
| EV / FCF | 9.29 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.42 |
| Quick Ratio | 2.68 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | 2.50 |
| Debt / FCF | 6.85 |
| Interest Coverage | 2.76 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -40.29% |
| Return on Assets (ROA) | 6.93% |
| Return on Invested Capital (ROIC) | 16.18% |
| Return on Capital Employed (ROCE) | 14.13% |
| Weighted Average Cost of Capital (WACC) | 10.56% |
| Revenue Per Employee | $855,778 |
| Profits Per Employee | -$196,444 |
| Employee Count | 900 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.19 |
Taxes
| Measure | Value |
|---|
| Income Tax | 30.80M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.29 |
| 52-Week Price Change | -27.55% |
| 50-Day Moving Average | 6.47 |
| 200-Day Moving Average | 8.01 |
| Relative Strength Index (RSI) | 52.98 |
| Average Volume (20 Days) | 1,067,589 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.68M |
| Short Previous Month | 9.79M |
| Short % of Shares Out | 18.89% |
| Short % of Float | 19.74% |
| Short Ratio (days to cover) | 8.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 770.20M |
| Gross Profit | 388.50M |
| Operating Income | 140.50M |
| Pretax Income | -146.00M |
| Net Income | -176.80M |
| EBITDA | 234.90M |
| EBIT | 140.50M |
| Loss Per Share | -$3.39 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 139.70M |
| Total Debt | 588.20M |
| Net Cash | -448.50M |
| Net Cash Per Share | -$8.75 |
| Equity (Book Value) | 341.40M |
| Book Value Per Share | 6.65 |
| Working Capital | 543.20M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 97.70M |
| Capital Expenditures | -11.80M |
| Depreciation & Amortization | 94.40M |
| Net Borrowing | -117.00M |
| Free Cash Flow | 85.90M |
| FCF Per Share | $1.68 |
Margins
| Measure | Value |
|---|
| Gross Margin | 50.44% |
| Operating Margin | 18.24% |
| Pretax Margin | -18.96% |
| Profit Margin | -22.96% |
| EBITDA Margin | 30.50% |
| EBIT Margin | 18.24% |
| FCF Margin | 11.15% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 5.35% |
| Shareholder Yield | 5.35% |
| Earnings Yield | -49.74% |
| FCF Yield | 24.60% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.00 |
| Price Target Difference | 61.53% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -5.44% |
| EPS Growth Forecast (3Y) | 0.83% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |